Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621)

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 990-996

  Fox, Elizabeth ^a   Mosse', Yael P ^a   Meany, Holly M ^b   Gurney, James G ^c   Khanna, Geetika ^d   Jackson, Hollie A ^e   Gordon, Gary ^f   Shusterman, Suzanne ^g   Park, Julie R ^h   Cohn, Susan L ⁱ   Adamson, Peter C ^a   London, Wendy B ^g,j   Maris, John M ^a   Balis, Frank M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f ABBOTT LABORATORIES   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h SEATTLE CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j Children Oncology Group Statistics and Data Center ^*  (United States)

more..

Author keywords

Childhood cancer; Clinical trial; Microtubule inhibitor; Neuroblastoma; Time to progression

Indexed keywords

AMINOTRANSFERASE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ILEUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOOD DISORDER; NAUSEA AND VOMITING; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE TRANSFUSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

CHILDHOOD CANCER; CLINICAL TRIAL; MICROTUBULE INHIBITOR; NEUROBLASTOMA; TIME TO PROGRESSION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CAPSULES; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; MALE; NERVOUS SYSTEM DISEASES; NEUROBLASTOMA; QUALITY OF LIFE; RECURRENCE; SALVAGE THERAPY; SULFONAMIDES; SUSPENSIONS; TREATMENT FAILURE; TUBULIN MODULATORS;

EID: 84901707950     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24900     Document Type: Article

References (16)

1. Matthay K, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis retinoic acid. N Engl J Med 1999; 341:1164-1173.
2. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-1334.
3. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369:2106-2120.
4. Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24:65-86.
5. Galmarini CM. ABT-751 (Abbott). Curr Opin Investig Drugs 2005; 6:623-630.
6. Meany HJ, Sackett DL, Maris JM, et al. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatr Blood Cancer 2010; 54:47-54.
7. Morton CL, Favours EG, Mercer KS, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007; 25:285-295.
8. Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006; 12:4882-4887.
9. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method-application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A:256-261.
10. Fox E, Maris JM, Widemann BC, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008; 14:1111-1115.
11. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: Feasibility, reliability, and validity. Ambul Pediatr 2003; 3:329-341.
12. Varni JW, Burwinkle TM, Katz ER, et al. The PedsQL in pediatric cancer: Reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer 2002; 94:2090-2106.
13. Varni JW, Burwinkle TM, Seid M, et al. The Peds QL™ as a pediatric population health measure: Feasibility, reliability, and validity. Ambul Pediatr 2003; 3:329-341.
14. Fox E, Maris JM, Cohn SL, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol 2010; 66:737-743.
15. Woolson R. Rank tests and a one sample logrank test for comparing observed survival data to a standard population. Biometrics 1981; 37:687-696.
16. US Department of Health and Human Services FDA editor. Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. Rockille, MD; U.S. Department of Health and Human Services; 2007.